In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

Abstract

Objectives: To compare the activity of tedizolid (formally known as torezolid and TR-700) with that of 15 agents against a collection of linezolid-resistant staphylococci (164 coagulase-negative staphylococci and 5 Staphylococcus aureus). Methods: Antimicrobial susceptibility tests were performed using the broth microdilution method following the recommendations of the CLSI. Results: All isolates were susceptible to vancomycin and tigecycline. Based on the MIC90 values, the potency of tedizolid against coagulase-negative staphylococci was .16-fold greater than that of linezolid. Tedizolid retained activity against most of the linezolid-resistant staphylococci tested, including multidrug-resistant isolates with elevated linezolid MICs (32 to .128 mg/L). Of the isolates, 79.2% and 31.4% were inhibited by tedizolid at ≤4 mg/L and ≤2 mg/L, respectively. Conclusions: The results of this study confirm the activity of tedizolid against linezolid-resistant staphylococci. This new oxazolidinone could have an important role as a potential therapeutic agent against multidrug-resistant staphylococci.